Notice: This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends XTLB vs. TPST, AFMD, ANEB, IXHL, FGEN, VRCA, MDCX, IRD, RAPT, and OKURShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Tempest Therapeutics (TPST), Affimed (AFMD), Anebulo Pharmaceuticals (ANEB), Incannex Healthcare (IXHL), FibroGen (FGEN), Verrica Pharmaceuticals (VRCA), Medicus Pharma (MDCX), Opus Genetics (IRD), RAPT Therapeutics (RAPT), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical preparations" industry. XTL Biopharmaceuticals vs. Tempest Therapeutics Affimed Anebulo Pharmaceuticals Incannex Healthcare FibroGen Verrica Pharmaceuticals Medicus Pharma Opus Genetics RAPT Therapeutics OnKure Therapeutics Tempest Therapeutics (NASDAQ:TPST) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Do institutionals & insiders have more ownership in TPST or XTLB? 22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 4.7% of Tempest Therapeutics shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is TPST or XTLB more profitable? XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% XTL Biopharmaceuticals N/A N/A N/A Does the MarketBeat Community believe in TPST or XTLB? Tempest Therapeutics received 21 more outperform votes than XTL Biopharmaceuticals when rated by MarketBeat users. However, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10065.79% Underperform Votes5234.21% XTL BiopharmaceuticalsOutperform Votes7971.82% Underperform Votes3128.18% Do analysts prefer TPST or XTLB? Tempest Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 2,762.87%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, TPST or XTLB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$1.53-0.46XTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/A Which has more volatility & risk, TPST or XTLB? Tempest Therapeutics has a beta of -1.78, indicating that its share price is 278% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Does the media refer more to TPST or XTLB? In the previous week, Tempest Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 1 mentions for Tempest Therapeutics and 0 mentions for XTL Biopharmaceuticals. Tempest Therapeutics' average media sentiment score of 0.38 beat XTL Biopharmaceuticals' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tempest Therapeutics Neutral XTL Biopharmaceuticals Neutral SummaryTempest Therapeutics beats XTL Biopharmaceuticals on 7 of the 13 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.14M$6.71B$5.03B$8.97BDividend YieldN/A3.07%4.81%4.06%P/E RatioN/A10.45133.1816.92Price / SalesN/A187.361,119.91116.20Price / CashN/A57.1640.6337.94Price / Book3.645.194.754.71Net Income-$1.78M$151.85M$118.34M$225.20M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL BiopharmaceuticalsN/A$1.49-4.5%N/A+59.7%$8.14MN/A0.00N/ATPSTTempest Therapeutics1.8676 of 5 stars$0.80flat$20.00+2,400.0%-83.1%$34.91MN/A-0.5320AFMDAffimed4.4145 of 5 stars$2.13-0.9%$13.50+533.8%-68.5%$34.29M$8.95M0.0076News CoverageGap DownANEBAnebulo Pharmaceuticals2.4175 of 5 stars$1.30-7.1%$8.00+515.4%-40.0%$33.71MN/A-4.674Gap UpHigh Trading VolumeIXHLIncannex Healthcare0.1672 of 5 stars$1.90+2.2%N/A-46.1%$33.52M$86,000.00-1.343FGENFibroGen2.5101 of 5 stars$0.33-3.0%N/A-46.1%$32.76M$180.02M-0.28486Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageVRCAVerrica Pharmaceuticals4.6721 of 5 stars$0.72-5.6%$9.50+1,223.1%-88.4%$32.74M$5.12M-0.4040MDCXMedicus PharmaN/A$2.95+7.3%N/AN/A$32.00MN/A0.00N/AAnalyst ForecastIRDOpus Genetics2.714 of 5 stars$1.00-2.0%$8.00+700.0%N/A$31.57M$8.38M-0.92N/AHigh Trading VolumeRAPTRAPT Therapeutics4.6878 of 5 stars$0.88-3.2%$9.50+978.0%-95.9%$30.81M$1.53M-0.3380OKUROnKure Therapeutics3.9426 of 5 stars$9.08-7.9%$36.00+296.5%N/A$30.33MN/A-0.81N/AHigh Trading Volume Related Companies and Tools Related Companies Tempest Therapeutics Competitors Affimed Competitors Anebulo Pharmaceuticals Competitors Incannex Healthcare Competitors FibroGen Competitors Verrica Pharmaceuticals Competitors Medicus Pharma Competitors Opus Genetics Competitors RAPT Therapeutics Competitors OnKure Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XTLB) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
